Should I Buy BMRA? BMRA 2026 Analysis

Should You Buy Biomerica Inc (BMRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

2.250

1 Day change

-0.88%

52 Week Range

8.800

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: the trend is decisively bearish (SMA_200 > SMA_20 > SMA_5) and momentum is still deteriorating (MACD histogram negative and expanding).
No Intellectia edge today: both AI Stock Picker and SwingMax show no buy signal, so there’s no strong short-term timing advantage for an impatient entry.
Financial quality is weakening (revenue down, gross margin collapsed), and there are no near-term news catalysts to spark a reversal.
With price trading below/near key supports (around S1/S2), downside risk remains elevated versus the limited statistical upside shown by pattern matching.

Technical Analysis

Trend: Bearish structure with moving averages stacked negatively (SMA_200 > SMA_20 > SMA_5), indicating an established downtrend.
Momentum: MACD histogram at -0.0305 (below zero) and negatively expanding → selling pressure is strengthening, not stabilizing.
RSI: RSI_6 = 27.26 (oversold territory). This can allow for a short bounce, but oversold alone is not a buy trigger when trend/momentum keep weakening.
Key levels: Pivot 2.464 (overhead resistance). Resistance: 2.575 (R1), 2.643 (R2). Support: 2.353 (S1), 2.285 (S2). Pre-market ~2.30 is near/below S1 and close to S2, suggesting fragile support.
Pattern-based expectation: Similar-pattern stats imply modest upside probabilities (next day +1.63%, week +1.47%, month +3.63%), but these are small compared with the broader bearish technical backdrop.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Reported put/call ratios at 0.0 likely indicate missing/illiquid options flow rather than strong bullish sentiment.
Historical volatility is high (73.23), implying elevated price swings and less reliable signal quality from small technical bounces.

Technical Summary

Sell

Buy

Positive Catalysts

can support a short-lived mean-reversion bounce if buyers defend the 2.285–2.353 support zone.

Neutral/Negative Catalysts

and hovering near lower supports (S1/S2), increasing risk of a breakdown.

Financial Performance

Latest quarter: 2026/Q2.
Revenue: 1.21M, down -26.04% YoY (clear top-line contraction).
Net income: -1.32M (still a loss), improved 38.95% YoY, but profitability remains negative.
EPS: -0.45, improved 2.27% YoY (small improvement, still meaningfully negative).
Gross margin: 4.21, down -84.24% YoY (major deterioration in core economics; this is a significant red flag).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price-target change data was provided, implying no clear recent Wall Street endorsement or catalyst from coverage.
Wall Street pros (based on what’s available): none evidenced in the dataset (no upgrades/targets, no notable institutional trend).
Wall Street cons (based on provided fundamentals/technicals): shrinking revenue, collapsing gross margin, continued losses, and a firmly bearish price trend.

Analyst Rating

Wall Street analysts forecast BMRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMRA is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 2.270

Low

Averages

High

Current: 2.270

Low

Averages

High

BMRA Should I Buy

BMRA Should I Buy

Should You Buy Biomerica Inc (BMRA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data

People Also Watch